CALCA and COVID-19: In this cohort study on CGRP mAb treatment and COVID-19 outcomes in veterans with migraine, there was no significant difference in the incidence of COVID-19 or sequela hospitalization between CGRP mAb recipients and nonrecipients, suggesting that CGRP mAbs may be used for migraine prevention among patients who are at risk of or have COVID-19.